Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025 CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces... Read More

CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock,... Read More

CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be... Read More

Initiated full U.S. commercial launch of AYON Body Contouring System ™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations Submitted new 510(k) for AYON for device label expansion to include power liposuction Increased total revenue guidance for FY2025 to a range of $50.5 million to $52.5 million Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., Nov. 06, 2025 (GLOBE... Read More

CLEARWATER, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® and the AYON Body Contouring System™, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conferences: Event: 16th Annual... Read More

CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th. Management... Read More

Initiated Nationwide Commercial Launch of AYON in September The Company is Hosting a Virtual Key Opinion Leader Event to Discuss the Commercial Launch of AYON on October 14, 2025 CLEARWATER, Fla., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion ® and... Read More

CLEARWATER, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® and the AYON Body Contouring System™, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 14, 2025 at 12:00 PM ET featuring Paul Vanek, Jr., MD, FACS... Read More

CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation , an advanced energy technology company and manufacturer of Renuvion® and the newly launched AYON Body Contouring System™, today announced the strategic appointments of two accomplished sales executives to its leadership team. These additions support the Company’s continued global expansion and the commercial launch of AYON, the industry’s first... Read More

CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John Featherstone, Apyx’s Vice President, North American Sales as a material inducement to such employee’s employment and in accordance with Nasdaq Listing Rule 5635(c)(4). The... Read More

Successfully launched AYON Body Contouring System ™ to key surgeons in critical geographies; plan for commercial launch in September 2025 Initiated commercial sales of Renuvion ® in China with strong clinical interest and completed initial procedures Based on pre-sales of AYON, the Company increased its total revenue guidance for FY2025 to a range of $50.0 million to $52.0 million Management to host a conference call today... Read More

CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® and the AYON Body Contouring System ™ , today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA.... Read More

Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance CLEARWATER, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced the launch of Renuvion ® in China as part of its international commercialization strategy. A... Read More

CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7 th.... Read More

Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla. , May 30, 2025 /PRNewswire/ -- Apyx ® Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion ® , is once again taking center stage—this time at Miami Swim Week.... Read More

The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary... Read More

Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last year U.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last year Preparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearance Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE)... Read More

Beloved Personality of "The Real Housewives of New Jersey" Provides a Real Take on the Problem of Loose Skin and the Power of Body Contouring Technology CLEARWATER, Fla. , May 1, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® today announces Dolores Catania as... Read More

Two studies report favorable clinical outcomes and safety data for Renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical” or the “Company”), the... Read More

CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00... Read More

Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla. , March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion... Read More

The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last year Submitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule and preparing for a planned launch in the back half of 2025, pending clearance Management to host a conference call today at 8:30 a.m. ET CLEARWATER,... Read More

CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx ® Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call... Read More

CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Revenue Summary Total revenue expected to be in a range of approximately... Read More

CLEARWATER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apyx ® Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , is pleased to announce it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System. The AYON Body Contouring... Read More

CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that management will participate in the Piper Sandler 36 th Annual Healthcare Conference on Wednesday, December 4, 2024, in New York, NY. Charlie Goodwin, the Company’s... Read More

CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: Event: 15th Annual Craig-Hallum Alpha Select Conference... Read More

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the... Read More

Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately $7.0 million; and amended revenue covenants for the Company’s credit agreement with Perceptive Announces cost savings restructuring program to better focus, optimize and streamline operations, including a nearly 25% reduction in U.S. workforce Announces 9% overall growth in single-use handpiece revenue and 15%... Read More

CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx ® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion ® , today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference... Read More

Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla. , Aug. 13, 2024 /PRNewswire/ -- Apyx ® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), a leader in advanced energy technology and the manufacturer of Renuvion ® , today announced that doctors named Renuvion as the #1 trusted body contouring technology in an independent survey... Read More

Demonstrates a statistically significant reduction in adverse events associated with the use of Renuvion following liposuction or body contouring, compared to the competing technology CLEARWATER, Fla. / Aug 08, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion ® ,... Read More

CLEARWATER, Fla. / Aug 08, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion ® , today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024... Read More

CLEARWATER, Fla. / Jul 25, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion ® , today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m.... Read More

Renuvion is the only device FDA-cleared for contracting subcutaneous tissue CLEARWATER, Fla. , June 26, 2024 /PRNewswire/ -- Apyx ® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will... Read More

CLEARWATER, Fla. / May 09, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024. First Quarter 2024 Financial... Read More

Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman CLEARWATER, Fla. / May 09, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced the... Read More

CLEARWATER, Fla. / Apr 25, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th. Management will host a conference call at 8:00 a.m. Eastern Time... Read More

Shaping the Future of Aesthetic Treatments with Advanced Medical Technology CLEARWATER, Fla. / Apr 11, 2024 / Business Wire / Apyx® Medical Corporation (NASDAQ:APYX) (the “Apyx Medical”; “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024. The Renuvion... Read More

Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the fourth quarter; increased 18% year-over-year in 2023 CLEARWATER, Fla. / Mar 21, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today reported financial results for its fourth... Read More

CLEARWATER, Fla. / Mar 04, 2024 / Business Wire / Apyx ® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st. Management will host a conference call at 8:00 a.m. Eastern... Read More

Presentation hosted by Dr. Michael Kluska to feature the results of a retrospective clinical study comparing the use of Renuvion to a competing technology when used in conjunction with liposuction or body contouring, demonstrating significantly fewer adverse events CLEARWATER, Fla. / Feb 21, 2024 / Business Wire / Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary... Read More

Analysis of data from 483 patients with a total of 1,184 body areas treated found the use of Renuvion for subcutaneous soft tissue contraction following liposuction demonstrated no new or increased risks for any area of the body, compared to the use of liposuction alone CLEARWATER, Fla. / Jan 22, 2024 / Business Wire / Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary... Read More

CLEARWATER, Fla. / Jan 08, 2024 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter 2023 Revenue Summary : Total revenue in a range of approximately $14.2 to... Read More

CLEARWATER, Fla. / Nov 28, 2023 / Business Wire / Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on... Read More

New facility includes senior, secured term loans of up to $45 million CLEARWATER, Fla. / Nov 09, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the Company and its subsidiaries have entered into a new, five-year credit agreement with Perceptive Credit Holdings IV,... Read More

Advanced Energy Sales increased 39% year-over-year in Q3 CLEARWATER, Fla. / Nov 09, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today reported financial results for its third quarter ended September 30, 2023, and updated its financial expectations for the full year ending December... Read More

CLEARWATER, Fla. / Nov 07, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , announced today that management will participate in the following upcoming investor conferences: The Stephens Annual Investment Conference at the Nashville Grand Hyatt in Nashville, TN Management will... Read More

CLEARWATER, Fla. / Oct 02, 2023 / Business Wire / Apyx ® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the third quarter of fiscal year 2023 will be released before the market opens on Thursday, November 9th. Management will host a conference call at 8:00 a.m. Eastern... Read More

Advanced Energy Sales increased 40% year-over-year in Q2 CLEARWATER, Fla. / Aug 10, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today reported financial results for its second quarter ended June 30, 2023, and reaffirms financial expectations for the full year ending December 31,... Read More

CLEARWATER, Fla. / Jun 29, 2023 / Business Wire / Apyx ® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the second quarter of fiscal year 2023 will be released after the market closes on Thursday, August 10th. Management will host a conference call at 5:00 p.m. Eastern... Read More

CLEARWATER, Fla. / Jun 14, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the Renuvion Micro Handpiece, a new addition to the Renuvion product family. The Renuvion Micro Handpiece... Read More

CLEARWATER, Fla. / May 11, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today reported financial results for its first quarter ended March 31, 2023, and updated financial expectations for the full year ending December 31, 2023. First Quarter 2023 Financial Summary Total revenue of... Read More

APYX Medical's Renuvion Becomes the Only Device that is FDA-cleared for Use Following Liposuction in Aesthetic Body Contouring Procedures CLEARWATER, Fla. , May 2, 2023 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX), the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as... Read More

CLEARWATER, Fla. / Apr 28, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the use of the Renuvion APR Handpiece “for coagulation of subcutaneous soft tissues following liposuction... Read More

CLEARWATER, Fla. / Apr 05, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the first quarter of fiscal year 2023 will be released before the market opens on Thursday, May 11th. Management will host a conference call at 8:00 a.m. Eastern Time... Read More

Advertising Industry's Largest Competition Recognizes Apyx Medical Device Campaign for Excellence in the Art of Advertising CLEARWATER, Fla. , March 27, 2023 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) , the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® ,... Read More

CLEARWATER, Fla. / Mar 16, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2022, and introduced financial expectations for the full year ending December 31, 2023. Fourth Quarter 2022 Financial... Read More

CLEARWATER, Fla. / Feb 27, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the use of the Renuvion APR Handpiece “for the delivery of radiofrequency energy and/or helium plasma... Read More

CLEARWATER, Fla. / Feb 21, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that the Company and its subsidiaries have entered into a new, five-year secured credit facility with MidCap Financial. The credit agreement provides for an up to $35 million facility consisting... Read More

CLEARWATER, Fla. / Feb 16, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the fourth quarter and fiscal year 2022 will be released before the market opens on Thursday, March 16th. Management will host a conference call at 8:00 a.m. Eastern... Read More

Episode to Feature Beverly Hills Plastic Surgeon Dr. Charles J. Galanis Performing Renuvion's Minimally Invasive Neck Procedure on Patient CLEARWATER, Fla. , Feb. 9, 2023 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) , the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that "The Balancing Act'' television show on Lifetime ® will broadcast... Read More

CLEARWATER, Fla. / Feb 01, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced it has submitted a 510(k) premarket notification (“510(k) submission”) for the Renuvion APR Handpiece to the U.S. Food and Drug Administration (“FDA”), supported by a clinical study and... Read More

FDA-Cleared, All-in-One Advanced Energy System Now Available for Medical Professionals CLEARWATER, Fla. , Jan. 25, 2023 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced the launch of its latest-generation Renuvion generator, the Apyx One Console , in the United States . The... Read More

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2022. Preliminary Fourth Quarter 2022 Revenue Summary : Total revenue in a range of $12.1 to $12.5 million, representing a decline of 28% to 26% year-over-year.... Read More

Direct-to-Consumer Marketing Shows How Results Can Be Achieved Using Minimally Invasive Technology CLEARWATER, Fla. , Jan. 3, 2023 /PRNewswire/ -- Apyx ® Medical Corporation (NASDAQ: APYX) , the manufacturer of Renuvion ® , a proprietary helium plasma and radiofrequency technology, today announces the launch of its first-ever direct-to-consumer brand campaign. Entitled #ThisIsMe, the campaign is aimed at U.S. consumers who... Read More